Close Menu

NEW YORK (GenomeWeb) – PreCyte has received a one-year, $300,000 grant from the National Cancer Institute to develop a blood-based lung cancer diagnostic based on its core Indicator Cell Assay Platform (ICAP) technology.

ICAP was originally developed at the Institute for Systems Biology in the lab of company Co-founder John Aitchison and involves the use of cultured cells as biosensors, exposing them to patient serum and analyzing the transcriptional effect.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.